Literature DB >> 29301732

Gastrointestinal lymphomas: French Intergroup clinical practice recommendations for diagnosis, treatment and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, SFH).

Tamara Matysiak-Budnik1, Bettina Fabiani2, Christophe Hennequin3, Catherine Thieblemont3, Georgia Malamut4, Guillaume Cadiot5, Olivier Bouché5, Agnès Ruskoné-Fourmestraux2.   

Abstract

INTRODUCTION: This document is a summary of the French Intergroup guidelines on the management of gastro-intestinal lymphomas, available on the web-site of the French Society of Gastroenterology, SNFGE (www.tncd.org), updated in September 2017.
METHODS: This collaborative work was realised under the auspices of several French medical societies and involved clinicians with specific expertise in the field of gastrointestinal lymphomas, including gastroenterologists, haematologists, pathologists, and radiation oncologist, representing the major French or European clinical trial groups. It summarises their consensus on the management of gastrointestinal lymphomas, based on the recent literature data, previous published guidelines and the expert opinions.
RESULTS: The clinical management, and especially the therapeutic strategies of the gastro-intestinal lymphomas are specific to their histological subtypes and to their locations in the digestive tract, with the particularity of gastric MALT lymphomas which are the most frequent and usually related to gastritis induced by Helicobacter pylori.
CONCLUSION: Lymphomas are much less common than epithelial tumours of gastro-intestinal digestive tract. Their different histological subtypes determine their management and prognosis. Each individual case should be discussed within the expert multidisciplinary team.
Copyright © 2017 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Gastric lymphoma; Intestinal lymphoma; MALT; National French recommendations

Mesh:

Year:  2017        PMID: 29301732     DOI: 10.1016/j.dld.2017.12.006

Source DB:  PubMed          Journal:  Dig Liver Dis        ISSN: 1590-8658            Impact factor:   4.088


  6 in total

1.  A dynamic predictive nomogram of long-term survival in primary gastric lymphoma: a retrospective study.

Authors:  Jinru Yang; Tao Liu; Ying Zhu; Fangyuan Zhang; Menglan Zhai; Dejun Zhang; Lei Zhao; Min Jin; Zhenyu Lin; Tao Zhang; Liling Zhang; Dandan Yu
Journal:  BMC Gastroenterol       Date:  2022-07-16       Impact factor: 2.847

2.  Effect of Helicobacter pylori eradication therapy on the response of MALT-Gastric lymphoma.

Authors:  Habiba Dabbebi; Hanene Elloumi; Chaima Kechiche; Eya Hammemi; Imed Cheikh; Ali Jmaa
Journal:  Tunis Med       Date:  2022 Janvier

Review 3.  Gastrointestinal lymphoma: the new mimic.

Authors:  Anusha Shirwaikar Thomas; Mary Schwartz; Eamonn Quigley
Journal:  BMJ Open Gastroenterol       Date:  2019-09-13

4.  Long-Term Clinical Outcomes of Gastric MALT Lymphoma: A Nationwide Multicenter Study in Korea.

Authors:  Joon Sung Kim; Jun Chul Park; Jong Yeul Lee; Ji Yong Ahn; Sun Hyung Kang; Hyo-Joon Yang; Su Jin Kim; Moon Kyung Joo; Jae Myung Park
Journal:  Front Oncol       Date:  2021-10-14       Impact factor: 6.244

Review 5.  MALT lymphoma: epidemiology, clinical diagnosis and treatment.

Authors:  Petruta Violeta Filip; Denisa Cuciureanu; Laura Sorina Diaconu; Ana Maria Vladareanu; Corina Silvia Pop
Journal:  J Med Life       Date:  2018 Jul-Sep

6.  Renaissance of Radiotherapy in Intestinal Lymphoma? 10-Year Efficacy and Tolerance in Multimodal Treatment of 134 Patients: Follow-up of Two German Multicenter Consecutive Prospective Phase II Trials.

Authors:  Gabriele Reinartz; Caroline Molavi Tabrizi; Ruediger Liersch; Hansjoerg Ullerich; Dominik Hering; Kay Willborn; Juergen Schultze; Oliver Micke; Christian Ruebe; Wolfgang Fischbach; Martin Bentz; Severin Daum; Christiane Pott; Markus Tiemann; Peter Moeller; Andreas Neubauer; Martin Wilhelm; Georg Lenz; Wolfgang E Berdel; Normann Willich; Hans T Eich
Journal:  Oncologist       Date:  2020-03-27
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.